Form 4: APLT CFO Granted 150,000 Restricted Stock Units

Applied Therapeutics' Chief Financial Officer, Leslie D. Funtleyder, was granted 150,000 Restricted Stock Units (RSUs) vesting over a two-year period.

Summary

• Leslie D. Funtleyder, Chief Financial Officer and Director of Applied Therapeutics, Inc. (APLT), was granted 150,000 Restricted Stock Units (RSUs).
• The transaction date for this grant was January 1, 2026.
• Each RSU represents a contingent right to receive one share of the Issuer's common stock.
• The RSUs will vest in equal monthly installments over a twenty-four-month period immediately following January 1, 2026.
• Vesting is contingent upon Ms. Funtleyder continuing to provide services to the company through each vesting date.
• The grant was made under the Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan.
• Following this transaction, Ms. Funtleyder beneficially owns 1,340,459 shares of common stock directly.

Sentiment

Score: 6

Explanation: Slightly positive, as it indicates continued executive alignment and retention through standard compensation practices, without any negative surprises.

Positives

• The RSU grant aligns the Chief Financial Officer's long-term interests with those of shareholders, as the value of the compensation is tied to the company's stock performance.
• Equity compensation is a standard practice for retaining and incentivizing key executives in the biotechnology sector.

Negatives

• The future conversion of RSUs into common stock will result in a degree of share dilution, although this is a common aspect of equity compensation plans.

Risks

• The value of the granted RSUs is subject to the future market price of Applied Therapeutics' common stock, which can be volatile.
• Failure to meet service conditions could result in forfeiture of unvested RSUs.

Future Outlook

The 150,000 compensatory RSUs will vest in equal monthly installments over a twenty-four-month period commencing January 1, 2026, subject to continued service.

Industry Context

The grant of Restricted Stock Units is a common form of long-term incentive compensation for executives in the biotechnology and pharmaceutical industries, aiming to align management's interests with shareholder value creation over time.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a component of executive compensation is a widely adopted practice across the biotech and broader technology sectors, comparable to compensation structures at companies like Moderna, Biogen, or Gilead Sciences.
• The vesting schedule of 24 months in equal monthly installments is a standard approach, providing a continuous incentive for executive retention and performance, similar to plans observed at peer companies.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for minor dilution upon RSU vesting, but increased alignment of executive interests with long-term stock performance.
• Employees (specifically the CFO): Provides long-term incentive compensation tied to company performance and encourages retention.

Next Steps

• The granted RSUs will begin vesting in equal monthly installments starting January 1, 2026, over the subsequent 24 months.

Key Dates

Recommendation

This Form 4 filing details a routine equity compensation grant to a key executive. While it signifies continued alignment of management interests with shareholders, it does not present new information that would fundamentally alter the investment thesis or warrant a change in stock recommendation.

Keywords

APLT, Applied Therapeutics, Leslie D. Funtleyder, Restricted Stock Units, RSU, Equity Incentive Plan, Insider Transaction, CFO, Director, Compensation